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The metazoan Hippo pathway is an essential tumour suppressor signalling cascade that ensures normal tissue
growth by co-ordinating cell proliferation, cell death and cell differentiation. Over the past years, various genetic
and biochemical studies in Drosophila and mammals have defined a conserved core Hippo signalling module,
composed of members of the Ste20-like kinase, the MOB co-activator and the AGC kinase families. In Drosophila,
stimulated Hippo kinase phosphorylates and thereby activates the Mats/Warts complex, which consequently
phosphorylates and inactivates the transcriptional co-activator Yorkie. In mammals, the counterparts of the Hippo/
Mats/Warts/Yorkie cascade, namely MST1/2, MOB1A/B, LATS1/2 and YAP/TAZ, function in a similar fashion. These
canonical Hippo pathways are so highly conserved that human MST2, hMOB1A and LATS1 can compensate for the
loss of Hippo, Mats and Warts in flies. However, recent reports have shown that Hippo signalling is more diverse
and complex, in particular in mammals. In this review, we summarize our current understanding of mammalian
LATS1/2 kinases together with their closest relatives, the NDR1/2 kinases. The regulation of the LATS/NDR family of
kinases will be discussed, followed by a summary of all currently known LATS/NDR substrates. Last, but not least,
the biological roles of LATS/NDR kinases will be reviewed with specific emphasis on recent discoveries of canonical
and non-canonical LATS/NDR functions in the extended Hippo pathway.
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Kinase substrates, Intracellular functions, T-loop, Hydrophobic motifIntroduction
The Hippo tumour suppressor pathway regulates cell
proliferation, cell death and cell differentiation in
multicellular organisms to ensure normal tissue develop-
ment [1,2]. The final output of Hippo signalling is the in-
hibition of the transcriptional co-activators Yorkie and YAP
(yes-associated protein) / TAZ (transcriptional co-activator
with PDZ-binding motif) in flies and mammals, respect-
ively [3]. Essentially, the core Hippo signalling module is
composed of members of the Ste20-like kinase, the MOB
(mps one binder) co-activator and the AGC (protein kinase
A(PKA)/PKG/PKC-like) kinase families [4]. In Drosophila,
the stimulated Ste20-like Hippo kinase phosphorylates and
thereby activates a complex composed of Mats (mob as
tumour suppressor) and the AGC Warts kinase. The Mats/Correspondence: a.hergovich@ucl.ac.uk
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reproduction in any medium, provided the orWarts complex then phosphorylates and inactivates the
transcriptional co-activator Yorkie. In mammals, the coun-
terparts of the Hippo/Mats/Warts/Yorkie cascade, namely
MST1/2 (mammalian Ste20-like serine/threonine kinases
1/2), MOB1A/B, LATS1/2 (large tumour suppressor 1/2)
and YAP/TAZ, function in a similar fashion. While all
core Hippo components upstream of Yorkie have been
defined as tumour suppressors in flies, Yorkie displays
proto-oncogenic properties [5]. In mammals, genetic
studies provided the same picture, namely that loss of
MST1/2 [6], MOB1A/B [7], or LATS1 [8] results in tumour
growth, while YAP overexpression is sufficient to induce tu-
mours [9]. Therefore, mammalian Hippo signalling has
been defined as a tumour suppressor pathway that is essen-
tial for the control of the proto-oncoproteins YAP/TAZ
[10,11]. Since the functions and regulation of YAP/TAZ
have been reviewed recently [3], we will focus in this re-
view only on the LATS-mediated regulation of YAP/TAZ.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Hippo and Wnt/TGFβ signalling we refer the reader to a
recent overview provided by Varelas and Wrana [12].
Drosophila Warts and mammalian LATS1/2 kinases
are members of the serine/threonine AGC class of protein
kinases [13]. More specifically, LATS1/2 have been classi-
fied as a subgroup of AGC kinases together with NDR1/2
(nuclear Dbf2 related kinases 1/2; also known as STK38/
STK38L), based on two unique characteristics, a conserved
N-terminal regulatory domain (NTR) and an insert be-
tween subdomains VII and VIII of the catalytic kinase
domain [4]. Like other AGC kinases, LATS/NDR kinases
are regulated by phosphorylation on the activation segment
motif (AS; also referred to as T-loop) and a C-terminally
located hydrophobic motif (HM), which will be discussed
later in more detail. Initially, our understanding of
LATS/NDR kinases was mainly based on genetic studies
performed in yeast and flies [4]. Therefore, before focusing
entirely on our current understanding of mammalian
LATS/NDR kinases, we feel that it is appropriate to give a
brief historic overview of key discoveries with respect to
core Hippo signalling.
In budding and fission yeast, the LATS/NDR kinases
Dbf2p and Sid2p were described as central members of
MEN/SIN signalling which is essential for proper mi-
totic exit [14], while the LATS/NDR kinases Cbk1 and
Orb6 were attributed functions in the regulation of
morphogenesis [4]. In Drosophila, Warts and Tricornered
(the counterparts of mammalian LATS1/2 and NDR1/2,
respectively) were discovered more than 10 years ago
[15-17], and subsequent studies established Warts and
Trc (Tricornered) as key players in Hippo signalling and
dendritic tiling, respectively [5,18]. Significantly, human
LATS1 and NDR1 were able to rescue the loss of Warts
and Trc function, respectively [19,20], strongly suggesting
that LATS/NDR functions are conserved between flies and
mammals [4]. In 2002, Tapon et al. reported the regulation
of Warts by the scaffolding protein Salvador (also known as
WW45 in mammals) [21]. However, the breakthrough for
Hippo signalling were five publications in 2003 [22-26],
demonstrating that the Ste20-like kinase Hippo is func-
tioning upstream of Warts in tissue growth control. Sig-
nificantly, one study even showed that human MST2 can
compensate for Hippo loss of function [26]. Subsequently,
Lai et al. described Mats (also known as dMOB1) as a key
regulator of Warts downstream of Hippo [27]. The same
study also showed that hMOB1A can rescue the lethality
associated with loss of Mats function in flies [27]. Next, the
Pan laboratory discovered first that proto-oncogenic Yorkie
was functioning downstream of Hippo/Warts/Mats signal-
ling [28], and then also showed the phospho-regulation of
Yorkie by Warts [9]. These studies enabled then the Pan
and Guan laboratories to establish how YAP (one of two
human counterparts of Yorkie) was regulated by LATS1/2phosphorylation in mammalian cells [9,29], which will be
discussed in more detail later.
Since these discoveries were published nearly a decade
ago, the Drosophila community has continued to discover
positive and negative regulators of Hippo signalling, which
has been reviewed in detail recently [5]. Based on our per-
sonal interest in kinase signalling in the Hippo pathway, we
will only briefly mention how additional kinases influence
Hippo signalling, besides Hippo/MST and Warts/LATS
kinases. Recently, the kinases Tao (thousand and one)
and HIPKs (homeodomain-interacting protein kinases) were
shown to regulate Hippo activity [30,31] and Yki function
[32,33], respectively. Both regulatory mechanisms appear to
be conserved from flies to humans, since human TAO1 can
also activate MST2 [31], and HIPK2 promotes YAP activity
in human cells [33]. In addition, Sik (salt-inducible kinase)
has recently been shown to be required for Hippo signalling
by phosphorylating Salvador in flies [34]. However, while
human SIK2 can also inhibit YAP activity in HEK293 cells,
the molecular mechanism must be different between flies
and mammals, since the phosphorylation site in Drosophila
Salvador is not conserved in mammals [34]. This molecular
difference was not so surprising, since the transcriptional
outputs of Hippo signalling are known to differ significantly
between flies and mammalian cells [35], and Bossuyt et al.
recently reported fundamental differences in the upstream
regulatory mechanisms of Hippo signalling between
Drosophila and mammals [36]. Nevertheless, in spite of
this growing complexity upstream of Hippo, Drosophila
genetics still supports a linear Mats/Warts/Yorkie cascade
downstream of Hippo [5]. In light of this canonical Hippo
signalling (Hippo signals to Mats/Warts, which then regu-
lates Yorkie), we review here the regulation and functions
of mammalian LATS1/2 kinases.
Regulation of mammalian LATS/NDR kinases
In spite of the fast progress with deciphering Warts and
LATS1/2 functions in flies and mammals, the mechanism
of NDR1/2 regulation by phosphorylation currently must
serve as a model for LATS1/2 regulation [4,37]. Therefore,
we will first describe how mammalian NDR1/2 kinases are
regulated, before highlighting our limited understanding
of the regulatory mechanism of mammalian LATS1/2
(see Table 1). As already mentioned, NDR1/2 kinases are
members of a subgroup of AGC kinases containing two
key regulatory phosphorylation sites [38], the Ser281/282
AS and Thr444/Thr442 HM, respectively [4]. Binding of
hMOB1A/B (the human counterparts of Mats) to the
NTR domain of NDR1/2, which is highly conserved from
yeast to humans and located N-terminally of the catalytic
domain [4,39], increases the auto-phosphorylation activity
of NDR1/2, thereby elevating Ser281/282 phosphorylation
on NDR1/2 [40]. In contrast, HM phosphorylation of
NDR1/2 is performed independently of NDR1/2 kinase
Table 1 Overview of the regulation of mammalian LATS/NDR kinases by phosphorylation
Kinase(s) Upstream kinase Site(s) Role of phosphorylation
NDR1/2 Auto-phosphorylation Ser281/Ser282 Essential for kinase activity [38,41,47]
NDR1/2 MST1/2 Thr444/Thr442 Crucial for kinase activity [38,41,43,44]
NDR1/2 MST3 Thr442 Crucial for kinase activity [45,46]
LATS1 Unknown mechanism# Ser909 Essential for kinase activity [48,49]#
LATS1 MST1/2# Thr1079 Essential for kinase activity [48,49]#
LATS1 Cdk1/cyclin B Thr490 Might play a role in mitosis [50]
Ser613
LATS1 NUAK1 Ser464 Controls LATS1 protein stability [51]
LATS2 Aurora A Ser83/Ser380 plays a role in mitosis [52-54]
LATS2 CHK1/2 Ser408 Plays a role in DNA damage signalling [55]




#The potential auto- and trans-phosphorylation events on LATS1/2 (on Ser909/Ser872 and Thr1079/Thr1041) are not yet dissected. Therefore, we can only predict
here that MST1/2 mainly phosphorylate Thr1079/Thr1041 on LATS1/2, based on the reported conserved regulatory mechanism between MST1/2 and NDR1/2 in
human cells [43,44] and Hippo and Warts/Trc in fly cells [57].
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and MST3, another member of the MST kinase family [42],
can phosphorylate NDR1/2 on Thr444/442 [43-46]. These
S281 and Thr444 phosphorylations occur independently of
Insulin/IGF-1/PDK1 signalling [38], but are counteracted
by PP2A (protein phosphatase type 2A), since recombinant
PP2A dephosphorylates NDR1 in vitro [38] and treatment
of cells with okadaic acid (OA), a potent PP2A inhibitor, in-
creases NDR1/2 phosphorylation levels [38,41,47]. NDR1/2
versions carrying S281/282A, S281D, S281E, T444/442A,
T444D or T444E mutations have dramatically reduced
kinase activities upon OA treatment [38,47], suggesting that
both regulatory sites on NDR1/2 are essential for NDR1/2
kinase activity, but cannot be mimicked by standard
phospho-mimetic alterations. Taken together, these bio-
chemical studies conducted by the Hemmings laboratory
defined the following regulatory mechanisms: (1) binding
of hMOB1A/B to the NTR of NDR1/2 triggers auto-
phosphorylation of NDR1/2 on Ser281/282, (2) MST1/2/3
kinases phosphorylate NDR1/2 on Thr444/442, and (3)
PP2A can dephosphorylate both sites on NDR1/2 .
Importantly, these regulatory mechanisms are more
complicated in mammalian cells. MST1/2 kinases also
phosphorylate hMOB1A/B on Thr12 and Thr35, thereby
increasing the affinity of hMOB1A/B towards NDR1/2
[58]. Moreover, NDR1 deficient in hMOB1A/B binding
cannot be phosphorylated by MST1 on Thr444 in S-phase
arrested cells [43], suggesting that hMOB1A/B binding to
NDR1/2 is required for the phosphorylation of both regu-
latory sites in human cells [39]. NDR1/2 are also regulated
by binding to hMOB2, which is a level of regulation that
does not exist with LATS1/2, since hMOB2 does not bindto LATS1/2 [39]. hMOB2 competes with hMOB1A/B for
binding to the NTR of NDR1/2, where hMOB2 binding
appears to be inhibitory, while hMOB1A/B binding is acti-
vating [59]. In addition, MICAL-1 (molecules interacting
with CasL 1) competes with MST1 for binding to the HM
of NDR1/2, thereby antagonizing MST1-induced NDR ac-
tivation [60]. The TORC2 (target of rapamycin complex 2)
can also interact with NDR1 in HeLa cells [61], however,
whether this interaction influences NDR1/2 activity is yet
to be determined. The subcellular localisation of NDR1/2
seems to provide a further level of regulation, since mem-
brane targeting of NDR1/2 is sufficient to trigger NDR1/2
phosphorylation and activation [62].
LATS1/2 also contain the two conserved key regulatory
phosphorylation sites of AGC kinases, the Ser909/872 AS
and Thr1079/Thr1041 HM, respectively [4]. Both sites
are phosphorylated in cells and are essential for LATS1
kinase activity, since LATS1 S909A or T1079A mutants
are inactive [48,49]. Like with NDR1/2, LATS1 activity
is counteracted by PP2A-mediated dephosphorylation
of the AS and HM, since OA treatment of mammalian cells
results in dramatically increased AS/HM phosphorylation
and kinase activity of LATS1 [49,58]. hMOB1A/B also bind
to the conserved NTR domain of LATS1/2 [49,63,64],
but whether this affects the auto-phosphorylation activity
of LATS1/2 is still undefined. Moreover, LATS1 deficient in
hMOB1A/B binding is inactive and does not phosphorylate
YAP [49,56], and in MOB1A/B double knock out (DKO)
keratinocytes LATS1/2 phosphorylation on the HM is
decreased, while MST1/2 appears unaffected [7], indicating
that LATS1/hMOB1 complex formation is required for
LATS1 phosphorylation and kinase activity. Additionally,
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ligase, which can influence LATS1/2 functionality by
decreasing hMOB1A/B levels [65]. Phosphorylation of
hMOB1A/B on Thr12 and Thr35 by MST1/2 further
plays a role in regulating LATS1/hMOB1 complex for-
mation, since T12A and T35A mutants of hMOB1A/B
did not bind to LATS1 [58]. MST1/2 also phosphorylate
LATS1/2 [48], but whether MST1/2 phosphorylate
only the HM of LATS1/2 is currently unknown. However,
in MST1/2-deficient liver cells, LATS1 S909 and T1079
phosphorylation was not impaired, although MOB1A/B
phosphorylation on Thr12/35 was absent [6]. In mouse
thymocytes MST1/2 phosphorylation of MOB1A/B also
functions independent of LATS1/2 [66], strongly suggesting
that LATS/MOB1 complex formation is not always essen-
tial for LATS phosphorylation/activation. The subcellular
localisation of LATS1 is also likely to play a role in the
regulation of LATS1 activity, since membrane targeting of
LATS1 increased LATS1 activity [49]. Significantly, mem-
brane targeting of Warts together with Mats was sufficient
to reduce tissue growth in Drosophila [67], suggesting that
the membrane bound pool of LATS1/2 might be physiolo-
gically relevant as well. In contrast, in mouse keratinocytes
LATS1/2 seem to be activated by MST1/2 in the nucleus
[68]. In summary, current evidence suggests that LATS1/2
are likely to be regulated in a similar fashion as already
reported for NDR1/2 [4]. AS and HM phosphorylations of
LATS1/2 are essential for kinase activation, but whether
these specific phosphorylation events are regulated through
hMOB1A/B-mediated auto-phosphorylation on Ser909/872
on one hand, and by MST1/2 phosphorylation of Thr1079/
1041 on the other hand, is yet to be defined experimentally.
Certainly, the subcellular localisation of LATS1/2 plays a
role in their activation as well. Very likely, different subcel-
lular pools of LATS1/2 are regulated differently dependent
on the cell type specific context.
Besides these regulatory AS and HM phosphorylations,
LATS1/2 kinases are controlled by additional phosphor-
ylation events (Table 1). LATS1 is phosphorylated on
Thr490/Ser613 by Cdk1/cyclin B, which could play a
role in mitosis [50]. LATS2 is phosphorylated on Ser83/
380 and Ser408 by Aurora A and CHK1/2, respectively,
which seems to play a role in mitotic progression and DNA
damage signalling [52-55]. Phosphorylation of LATS2 by
PKA on Ser172/380/592/598 further stimulates LATS2
activity towards YAP [56]. Loss of PKA phosphorylation on
LATS2 neither affects the LATS2/hMOB1 interaction,
nor alters the AS and HM phosphorylations of LATS2,
although the LATS2 kinase activity towards YAP is im-
paired [56]. This suggests that other activating factors such
as changes in subcellular localisation and structural con-
formation might be dependent on PKA phosphorylation
of LATS1/2. Moreover, phosphorylation of LATS1 by
NUAK-1 (novel (nua) kinase family 1) on Ser464 controlsLATS1 protein stability [51]. However, whether this phos-
phorylation event regulates the ubiquitin-mediated degrad-
ation of LATS1 by the Itch and WWP1 E3 ligases [69-71]
is currently unknown. Furthermore, LATS1/2 protein
stability can be controlled by HSP90 [72] and ROS-PKC
delta signalling [73]. Significantly, LATS2 expression levels
are further regulated on the transcriptional level by the
transcription factors FOXP3 and p53 [74,75]. LATS2 ex-
pression is also regulated by TTP (tristetraprolin), an ARE
(AU-rich element) binding protein that promotes the deg-
radation of ARE-containing transcripts [76], and at least
six different microRNAs have been shown to negatively
regulate LATS2 expression [77-81].
Besides the regulatory protein-protein interaction (PPI)
between hMOB1A/B and LATS1/2 kinases [39], mamma-
lian Hippo signalling is regulated by additional PPIs which
directly or indirectly affect LATS/NDR activity [2,82].
Due to the emphasis of this review, we focus on discussing
reported direct PPIs of LATS1/2 with scaffolding/adaptor
proteins. Scribble has been shown to link MST/LATS/
YAP/TAZ complexes, thereby facilitating LATS phos-
phorylation of YAP/TAZ [83]. The Angiomotin proteins
AMOT, AMOTL1 and AMOTL2 can bind to and activate
LATS1/2 kinases [84], in addition to forming AMOT/YAP
and AMOT/TAZ complexes [85-87]. The mammalian
Ajuba LIM proteins, Ajuba, LIMD1 and WTIP, can interact
with LATS1/2, which seems to decrease LATS1/2 phos-
phorylation of YAP [88,89], suggesting that Ajuba LIM
proteins are negative regulators of LATS1/2 activity. Kibra
overexpression appears to stimulate Thr1079 phosphoryl-
ation by binding to LATS1 [90], while depletion of Kibra
caused a decrease of LATS1 phosphorylation on Ser909
[91]. However, the involvement of endogenous MST1/2
and hMOB1A/B in these regulatory PPIs are yet un-
known, therefore it is currently not possible to describe
in more detail how these scaffolding/adaptor proteins
regulate LATS1/2.
Substrates of mammalian LATS/NDR kinases
As already mentioned, LATS1/2 phosphorylation of
YAP/TAZ is a key event of the canonical Hippo pathway
(Tables 2 and 3). LATS1/2 phosphorylate YAP on Ser61/
109/127/164/381 [29,92] and TAZ on Ser66/89/117/311
[93], which led to the definition of a HXRXXS/T con-
sensus motif for LATS1/2 kinases. YAP phosphorylation
on Ser127 increases 14-3-3 binding to YAP, which results in
the cytoplasmic retention of inactive Ser127-phosphorylated
YAP [9,29,94]. In contrast, phosphorylation of YAP on
Ser381 regulates YAP protein stability [95]. TAZ phos-
phorylation on Ser89 and Ser311 follows a very similar
principle, with Ser89 phosphorylation facilitating 14-3-3
binding and cytoplasmic retention of TAZ [93,96,97] and
Ser311 phosphorylation regulating TAZ protein stability
[98]. In summary, LATS1/2-mediated phosphorylation of
Table 2 Summary of reported targeting motifs of
LATS/NDR substrates
Targeting motif Kinase(s) Target site
HVRGDpS LATS1/2 YAP on Ser61 [29,92]
HSRQApS LATS1/2 YAP on Ser109 [29,92]
HVRAHpS LATS1/2 YAP on Ser127 [29,92]
HLRQSpS LATS1/2 YAP on Ser164 [29,92]
HSRDEpS LATS1/2 YAP on Ser381# [29,92]
HSRQSpS LATS1/2 TAZ on Ser66 [93]
HVRSHpS LATS1/2 TAZ on Ser89 [93]
HLRQQpS LATS1/2 TAZ on Ser117 [93]
HSREQpS LATS1/2 TAZ on Ser311 [93]
LRKTGpS LATS1 MYPT1 on Ser445 [99]
GARRSpS LATS2 14-3-3γ on Ser59 [55]
HVRTHpT LATS2 Snail1 on Thr203 [100]
KRRQTpS NDR1/2 p21 on Ser146 [45]
HRRILpS NDR1/2 AAK1 on Ser635 [101]
HTRNKpS NDR/2 Rabin8(mouse) on Ser240 [101]
HTRNKpS NDR2 Rabin8(human) on Ser272 [102]
HXRXXpS/T
#S381 of YAP2 corresponds to S397 of YAP1.
Note:
PI4KB, Panx2, and Rab11fip5 sequences are not shown, since they are not yet
confirmed as direct substrates of NDR1/2 [101]. However, these three
substrates also display the HXRXXS/T motif [101].
Table 3 Summary of known direct downstream events/substr
Kinase(s) Substrate
LATS1/2 YAP on Ser61
LATS1/2 YAP on Ser109
LATS1/2 YAP on Ser127
LATS1/2 YAP on Ser164
LATS1/2 YAP on Ser381
LATS1/2 TAZ on Ser66
LATS1/2 TAZ on Ser89
LATS1/2 TAZ on Ser117
LATS1/2 TAZ on Ser311
LATS1 MYPT1 on Ser445
LATS2 14-3-3γ on Ser59
LATS2 Snail on Thr203
NDR1/2 p21/Cip1 on Ser146
NDR1/2 AAK1 on Ser635
NDR1/2 Rabin8 on Ser240#
NDR2 Rabin8 on Ser272#
NDR1/2 PI4KB on Ser277*
NDR1/2 Panx2 on Ser514*
NDR1/2 Rab11fip5 on Ser307*
#NDR kinases can phosphorylate the same conserved motif in mouse and human R
*Potential substrates that have yet to be confirmed as direct substrates.
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two levels, namely (1) cytoplasmic retention/nuclear
exclusion of YAP/TAZ, and (2) decreasing protein stability
of YAP/TAZ [3].
Not surprisingly, LATS1/2 have additional substrates in
mammalian cells (Tables 2 and 3). LATS1 phosphorylates
MYPT1 (myosin phosphatase-targeting subunit 1) on
Ser445, thereby promoting MYPT1 phosphatase activity
[99]. LATS2 also phosphorylates 14-3-3γ on Ser59 [55] and
Snail1 on Thr203 [100], which influences P-body formation
and Snail1 protein stability, respectively. The phosphoryl-
ation of 14-3-3 by LATS2 is particularly intriguing, since
this might represent an additional regulatory level of
the 14-3-3/YAP interaction that drives the cytoplasmic
retention of inactive YAP. LATS2 can also phosphorylate
DYRK1A (dual-specificity tyrosine-(Y)-phosphorylation-
regulated kinase 1A), which enhances DYRK1A kinase
activity and thereby possibly plays a role in RB-mediated
senescence [103]. Significantly, the phosphorylation motifs
in MYPT1 and 14-3-3γ do not align with the postulated
HXRXXS/T consensus motif for LATS1/2 kinases, but
rather display the basic R/KXXS/T motif, which is very
common amongst AGC kinases [13].
NDR1/2 kinases have three documented substrates
(Tables 2 and 3). NDR1/2 phosphorylate the cell cycle regu-
lator p21/Cip1 on Ser146, thereby regulating p21 protein
stability [45]. NDR1/2 also phosphorylate murine AAK1ates of LATS/NDR kinases
Role of phosphorylation
Not specifically determined [29,92]
Not specifically determined [29,92]
Facilitates 14-3-3 binding/cytoplasmic retention [9,29,94]
Not specifically determined [29,92]
Regulation of YAP protein stability [95]
Not specifically determined [93]
Facilitates 14-3-3 binding/cytoplasmic retention [93,96,97]
Not specifically determined [93]
Regulation of TAZ protein stability [98]
Promotes MYPT1 phosphatase activity [99]
Regulation of 14-3-3γ in P-body formation [55]
Regulating of Snail1 protein stability [100]
Regulates p21 protein stability [45]
Dendrite and spine development in neurons [101]
Dendrite and spine development in neurons [101]
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nucleotide exchange factor) on Ser635 and Ser240, re-
spectively [101]. NDR2 has further been shown to phos-
phorylate Rabin8 on Ser272 in human cells [102], which
is the same site as previously reported for mouse Rabin8
phosphorylation on Ser240 (Tables 2 and 3). NDR1 can
also phosphorylate YAP in vitro [92], however, the in vivo
phosphorylation of YAP by NDR1/2 has not been docu-
mented so far. Intriguingly, two of three NDR1/2 substrates
are also phosphorylated on the HXRXXS/T motif (Table 2),
suggesting that the HXRXXS/T motif might be a common
feature of LATS1/2 and NDR1/2 kinases. This speculation
is further support by the notion that LATS1 and NDR1
display the same peptide substrate preferences in vitro,
with the ideal substrate peptide containing the HXRXXS/
T motif [92].
Of course, the substrate phosphorylations by LATS/
NDR are counteracted by protein phosphatases to en-
able cells to rapidly adapt their signalling outputs, hence
it is not surprising that PP1A was reported to mediate
the dephosphorylation of YAP/TAZ [104,105]. PTPN14
(non-receptor tyrosine phosphatase 14) has also been
shown to regulate YAP function, but whether this regula-
tion is dependent of PTPN14 tyrosine phosphatase activity
is currently debatable [106]. Possibly, PTPN14 influences
the Tyr phosphorylation of YAP by c-Abl [107] than playing
a role in counter balancing LATS1/2 substrate phosphory-
lation. However, since PKL01, a LATS/NDR homologue in
plants, has recently been shown to be a dual-specificity ki-
nase that can phosphorylate Ser/Thr and Tyr residues
[108], it is tempting to speculate that it is just a question of
time until the LATS/NDR substrate spectrum will be ex-
panded to Tyr phosphorylations. Last, but not least, we
would like to stress that current genetic evidence from Dros-
ophila studies [5] suggests Warts (the fly counterpart of
LATS1/2) is very likely to have additional substrates besides
Yorkie (the fly counterpart of YAP/TAZ). In this context, it
is noteworthy that Thompson and colleagues recently
reported that Warts phosphorylates and inhibits the actin
regulator Enabled, thereby restricting F-actin polymerization
to local migrating clusters [109]. These findings suggest that
the mammalian counterpart(s) of Enabled are very likely to
also represent novel LATS1/2 substrates, besides pointing
out that Drosophila genetics combined with biochemical
approaches are likely to keep on pointing the way with
regard to discovering novel LATS/NDR substrates.
Functions of mammalian LATS/NDR kinases
In Drosophila, loss of the tumour suppressor Warts
(the fly counterpart of mammalian LATS1/2) is larval
lethal [16,17]. In contrast, LATS1 knock-out (KO) mice are
viable [8], while LATS2 knock-out mice die during embry-
onic development, most likely due to defective cytokinesis
resulting in genomic instability [64,110]. However, LATS1null animals develop tumours [8], and immortalised LATS2
null MEFs display loss of contact inhibition [64,110], indi-
cating that LATS1/2 might function as tumour suppressors
in mammals [10]. LATS1/2 whole body DKO animals have
not been reported yet. Nevertheless, a study combining
LATS2 KO with RNAi depletion of LATS1 has shown
that LATS1/2 kinases are crucial for early embryonic de-
velopment [111]. More specifically, LATS1/2 are required
to distinguish between trophectoderm and inner cell
mass in preimplantation mouse embryos [111]. LATS1/2
also play a role in heart development [112,113], since inter-
ference with LATS1/2 function by either overexpressing
dominant-negative LATS2 [112] or heart specific deletion
of LATS1/2 [113] resulted in heart abnormalities. Taken
together, LATS1/2 play important roles in embryonic deve-
lopment and heart formation, besides functioning as tumour
suppressors in mammals.
While studies of tissue specific ablation of LATS1/2
function in animals are still limited in number, the roles
of LATS1/2 as major regulators of the YAP/TAZ proto-
proteins are well established [1,2]. In canonical Hippo
signalling MST1/2 activated LATS1/2 phosphorylate
YAP/TAZ on Ser127/89 and Ser381/311, respectively,
thereby controlling YAP/TAZ on two levels: (1) Ser127/89-
mediated spatial regulation (nuclear-cytoplasmic shuttling)
and (2) Ser381/311-mediated phospho-degron mediated
temporal regulation (degradation) (see Tables 2 and 3).
However, the spatial regulation of YAP by LATS1/2 appears
to be more complicated, since in sparse human and murine
cell lines Ser127/112-phosphorylated YAP can also be
detected in nuclei [114]. Moreover, the model of MST1/
2-LATS1/2 mediated regulation of YAP has been chal-
lenged by studies of MST1/2 and YAP KO animals. First,
liver specific deletion of MST1/2 in mice causes hepato-
cellular carcinoma (HCC) by YAP deregulation without
any apparent involvement of LATS1/2 [6]. Second, YAP is
negatively regulated in keratinocytes without any apparent
involvement of MST1/2 or LATS1/2 signalling [115]. Third,
in mouse thymocytes MST1/2 mainly signals through
phosphorylation of MOB1A/B without any apparent
involvement of LATS1/2 or YAP [66]. Fourth, in the
mouse intestine YAP displays a growth-suppressive func-
tion restricting Wnt signals during intestinal regeneration
[116]. These studies suggest that (1) MST1/2 does not
always signal through LATS1/2 to YAP, (2) MST/LATS
signalling are dispensable for YAP regulation in specific
cell types, (3) MST1/2 signalling can function com-
pletely independent of the LATS/YAP signalling branch
in specialised cell types, and (4) YAP does not always
function as a proto-oncoprotein, but could also have con-
text dependent tumour suppressive activity in the colon.
This last point is also supported by studies of breast can-
cer patients, which currently suggest that YAP might have
oncogenic and tumour suppressive functions dependent on
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appears to evolve with respect to the role of YAP in colon
cancer, since Camargo and colleagues found that YAP is
silenced in a subset of highly aggressive and undifferen-
tiated human colorectal carcinomas [118], while other
studies suggest that YAP functions as a proto-oncoprotein
in the colon [3]. The regulation of YAP in HCC is also not
completely clear. In a significant fraction of human HCC
samples Zhou et al. detected a correlation between de-
creased phospho-S127 YAP and decreased MST1 activity,
arguing that MST1/2 activity is a key determinant upstream
of YAP [6]. In contrast, Li et al. reported that in their HCC
samples phospho-Ser127 YAP is decreased together with
phosphorylated LATS1/2, while MST1/2 activity, as judged
by the phosphorylation status of MST1/2, was not affected
[119]. In summary, these findings illustrate that in human
breast, colon and hepatic malignancies the role of the
MST1/2-LATS1/2-YAP axis will most likely need to be
defined based on cancer subtypes.
Significantly, LATS1/2 signalling could play a further
role in mammalian stem cells [116,120]. YAP needs to
be inactivated during the differentiation process of mur-
ine embryonic stem (ES) cells and elevated during iPS
(induced pluripotent stem cells) reprogramming, illustrat-
ing that YAP is a critical regulator of stem cell pluripotency
[121]. However, in these settings the regulation of YAP by
LATS1/2 is yet to be defined. This point is important, since
Zhou et al. showed that MST1/2 signalling plays a crucial
role in YAP regulation in colon stem cells without apparent
involvement of LATS1/2 signalling [122], suggesting that
the regulation of YAP in stem cells might not always de-
pend on LATS1/2. Nevertheless, knockdown of LATS2 can
increase the efficiency of the formation of human iPS, most
likely by releasing the normal repressive function of LATS2
as TAZ antagonist [79]. Therefore, LATS1/2 appear to be
key players in mammalian stem cell biology, although much
work is yet to be done to understand precisely how LATS1/
2 function upstream of YAP/TAZ in this specific cell type.
Whatever the case might be in cancer and stem cells, in
mostly normal human cell lines (in particular HEK293
and MCF10A cells) LATS1/2 function downstream of
G-protein-coupled receptors (GPCRs) as central controllers
of YAP/TAZ activities [2]. The Guan and Wu laborator-
ies discovered that LPA (lysophosphatidic acid) and S1P
(Sphingosine-1-phosphate) are major serum components
responsible for YAP/TAZ activation [123,124]. More
specifically, Yu et al. showed that LPA and S1P act
through G12/13-coupled receptors to inhibit LATS1
S909/T1079 phosphorylation and activity, thereby allowing
the dephosphorylation and consequent activation of
YAP/TAZ [124]. Stimulation of protease-activated recep-
tors (PARs; another group of GPCRs) also results in the
inhibition of LATS1 activity due to decreased Ser909 and
Thr1079 phosphorylation, which results in decreased YAP1S127 phosphorylation, consequently allowing nuclear
accumulation of active YAP [125]. Moreover, Guan and
colleagues found that glucagon and epinephrine act
through Gs-coupled receptors to stimulate LATS1 S909/
T1079 phosphorylation, followed by phosphorylation and
inhibition of YAP by activated LATS1/2 [124]. Signifi-
cantly, these studies further suggest that GPCR signalling
acts through Rho GTPases to trigger changes in LATS1/2
phosphorylation completely independent of MST1/2 sig-
nalling [124,125]. This raises the question how Ser909 and
Thr1079 phosphorylation of LATS1/2 is regulated in this
setting (see also Table 1). Potentially, changes in actin dy-
namics modulate these phosphorylation events [2], but the
molecular mechanisms are currently not understood.
EGF (epidermal growth factor) signalling seems also to
be able to regulate Hippo signalling in MCF10A cells
[126], which is supported by a recent genetic study in
Drosophila [89]. However, the role of EGF/EGFR signalling
upstream of the Hippo pathway is currently debatable,
since data from the Guan laboratory suggest that EGF
has no significant effect on YAP phosphorylation [29,124].
In spite of these conflicting results, it is currently undis-
puted that LATS1/2 also function outside of the canonical
Hippo pathway [127]. The Kolch and O’Neill laboratories
have shown that K-ras signalling can function upstream of
MST2-LATS1 in non-canonical Hippo signalling [128,129].
MST2 and LATS1/2 further play a role in Raf-1 activation
by regulating the levels of the catalytic phosphatase subunit
PP2A-C [130]. Moreover, LATS2 can regulate the levels of
the p53 tumour suppressor by binding to Mdm2, the E3
ligase of p53 [75]. LATS1/2 have also been reported as
regulators of different G1/S, G2/M, and mitotic cell
cycle checkpoints, which have already been summarised
elsewhere [14,127]. Taken together, LATS1/2 are central
players in the regulation of YAP/TAZ functions in can-
cer and stem cell biology, although LATS1/2 also play
significant roles in non-canonical Hippo signalling and
even Hippo independent pathways.
While the activation mechanism of NDR1/2 is much
better understood than the one of LATS1/2, much less
is known about the biological functions of NDR1/2.
NDR1 KO mice are viable, but develop T-cell lymphoma,
most likely due to defective pro-apoptotic signalling [131].
NDR2 KO mice or NDR1/2 DKO animals have not been
reported yet, however, dogs carrying a mutation in NDR2
display retinal degeneration [132]. Furthermore, it has been
reported that human NDR1/2 play a role in centrosome
duplication in S-phase [43,133], contribute to mitotic
progression [134,135], and regulate the G1/S cell cycle
transition by phosphorylating p21 [45]. Moreover, NDR1
regulates the protein stability of the proto-oncoprotein
c-myc [45,136-138]. However, the mechanism of c-myc
regulation by NDR1 is currently debatable, since Califano
and colleagues reported that it is kinase activity dependent
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pendent of NDR1 activity [45,137]. Taken together, these
reports suggest that NDR1/2 are important cell cycle reg-
ulators. The regulation of the G1/S cell cycle transition by
NDR1/2 can be explained by the negative regulation of
the p21 cell cycle inhibitor combined with the positive
regulation of c-myc levels [137]. However, the substrates
functioning downstream of NDR1/2 in S-phase and mitosis
are yet to be defined.
NDR1 functions additionally in apoptotic signalling
[44,60,131], and has also been reported to play some role in
oxidative stress MAPK (mitogen-activated protein kinase)
signalling [139,140]. Furthermore, NDR2 has recently been
described as regulator of ciliogenesis via phosphorylating
Rabin 8 [102]. Last, but not least, Jan and colleagues
reported recently [101] the identification of the first NDR1/
2 substrates in neurons (see Tables 2 and 3). The authors
functionally validated two substrates, showing that AAK1
and Rabin 8 function downstream of NDR1/2 in neuronal
dendrite and synapse formation [101]. In summary, NDR1/
2 function in the regulation of cell cycle progression,
centrosome biology, stress/apoptotic signalling, and neur-
onal dendrite/synapse formation.
Mammalian LATS/NDR kinases, centrosomes and the actin
cytoskeleton
As already mentioned NDR1/2 kinases play a part in
centrosome biology, most likely by associating with centro-
somes [43,102,133]. LATS1/2 have also been detected on
centrosomes [4], but the centrosomal function of LATS1/2
is currently not well understood. Nevertheless, two factors
involved in centrosome-based ciliogenesis, NPHP4 and 9
(nephrocystin proteins 4 and 9), have been shown to regu-
late YAP/TAZ function [141,142]. NPHP4 interacts with
LATS1 and inhibits LATS1 mediated phosphorylation of
YAP and TAZ [141,142], while NPHP9 targets TAZ to the
nucleus in a TAZ/NPHP9 complex [142]. Whether these
regulatory processes involve cytoskeletal changes is cur-
rently unclear, although YAP/TAZ are downstream effec-
tors of changes in the extracellular matrix, cell adhesion,
cell shape and the cytoskeleton [143].
In particular, the actin cytoskeleton has recently gained
more attention in the Hippo community. In Drosophila
and human cells F-actin remodelling alters Hippo signalling
[144]. Piccolo and colleagues found that YAP/TAZ are
downstream of mechanical signals that are influenced
by extracellular matrix rigidity and cell shape [145].
Significantly, this process is dependent on Rho GTPase
activity and F-actin dynamics, but appears to be independ-
ent of LATS1/2 signalling [145]. The Sasaki laboratory also
reported a regulation of YAP by cell morphology in an
F-actin dependent manner, although their data suggest that
LATS1/2 are involved in this process [114]. In support
of the model which places F-actin dynamics upstream ofLATS1/2 to regulate YAP, Zhao et al. showed that cell
attachment and cytoskeleton remodelling regulates LATS1/
2 activity and consequently YAP activity [146]. Moreover,
in human cells GPCR signalling acts through F-actin re-
modelling to trigger changes in LATS1/2 activity towards
YAP/TAZ [124,125]. Based on these findings the role of
LATS1/2 in these settings is debatable, however, all these
studies fully agree that YAP/TAZ function as sensors and
mediators of mechanical inputs which are influenced by
the cellular architecture and microenvironment.
Intriguingly, it has been reported that LATS1 can bind
to actin and inhibit actin polymerisation [147]. Moreover,
LATS1 interacts with Zyxin [148] and LIMK1 [149], two
regulators of actin filament assembly. These findings sug-
gest that LATS1 might also function in mechanosensing,
maybe even independent of YAP/TAZ. Whatever the case,
in Drosophila, mutation of Warts results in altered F-actin
levels [150], suggesting that Warts is required for normal
actin dynamics. Not surprisingly, the same study also
showed that Trc mutants have altered levels of F-actin
[150], because it has already been speculated since the year
2000 that the actin cytoskeleton might be a Trc target [15].
However, it is currently not established whether NDR1/2
kinases can also regulate F-actin remodelling, although a
NDR2/actin complex has been reported nearly a decade
ago [151]. In summary, actinomyosin dynamics play an
important role in the control of the Hippo pathway.
Conclusions
While the involvement of LATS/NDR in the regulation
of the actin cytoskeleton is yet to be elucidated in more
detail, it is undisputed that YAP/TAZ function as sensors
and mediators of mechanical inputs coming from the cellu-
lar architecture and microenvironment. Besides F-actin re-
modelling, changes in the microtubule cytoskeleton should
also to be considered in future studies, since the Guan
laboratory could already show that LATS1/2 activity is
modulated by anti-microtubule drugs [146]. It is note-
worthy that hMOB1A/B, a key regulator of LATS/NDR
kinases [39], has recently been shown to control micro-
tubule dynamics [152], suggesting that LATS/NDR might
also function as regulators of the microtubule cytoskeleton.
The role of MST1/2 in cytoskeletal signalling is also not
fully understood. Importantly, in this context, cell type
dependent roles must be considered, since MST1/2 is
dispensable for LATS1/2 signalling in MEFs, but not in
HeLa cells [146].
Future research is further needed to decipher how
LATS1/2 are regulated by hMOB1A/B and MST1/2,
since currently the mechanism of NDR1/2 regulation by
phosphorylation must serve as the model for LATS1/2
regulation. NDR1/2 are mainly controlled (1) by bind-
ing of hMOB1A/B to the NTR of NDR1/2 triggering
auto-phosphorylation of NDR1/2 on the AS, and (2) by
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Phosphorylation of LATS1/2 on the conserved AS and
HM regulatory sites is also essential for LATS1/2 kinase
activity, but the molecular regulatory mechanisms of these
phosphorylation events are currently not understood.
The regulation of LATS/NDR activities is even more
complex in cells, since MST1/2-mediated phosphorylation
of hMOB1A/B influences hMOB1/LATS and hMOB1/
NDR complex formation. In addition, changes in subcellu-
lar localisation, additional phosphorylation events, and
competition between activating and inhibitory factors for
kinase binding influence LATS/NDR activities. Further-
more, MST1/2 signalling is dispensable for LATS/NDR
phosphorylation in selected cell types and biological func-
tions, indicating that additional upstream kinases of LATS/
NDR need to be studied in the future. In this context, it is
worth mentioning that McCollum and colleagues recently
reported that the activities of the yeast LATS/NDR kinases
Sid2 and Orb6 are cross-regulated by Sid2 phosphorylating
Nak1, the upstream Hippo kinase of Orb6 in yeast [153].
This raises the interesting possibility that human LATS1/2
and/or NDR1/2 might function upstream of each other in
specific settings. However, this form of cross-regulation has
yet to be reported in mammals.
To date, the best characterised LATS1/2 function is
the regulation of YAP/TAZ by phosphorylation, thereby
playing a crucial role in mammalian cancer and stem cell
biology. In canonical Hippo signalling LATS1/2 phos-
phorylate YAP/TAZ on Ser127/89 and Ser381/311,
respectively, thereby controlling YAP/TAZ on two levels,
namely Ser127/89-mediated spatial regulation and Ser381/
311-mediated temporal regulation. However, LATS1/2 also
function in non-canonical Hippo signalling and even in
Hippo independent pathways, thereby playing roles in Ras/
Raf-1 signalling, the regulation of p53, and cell cycle pro-
gression. In contrast to LATS1/2, NDR1/2 functions have
only recently been reported, proposing that NDR1/2 func-
tion in the regulation of cell cycle progression, centrosome
biology, stress/apoptotic signalling, and neuronal dendrite/
synapse formation. The recently reported mitochondrial
role of Trc [154] will potentially provide a further platform
to discover more roles of NDR1/2 in mammals. Taken
together, given the recent research progress on LATS/
NDR functions, we believe that more key functions of
LATS/NDR are yet to be discovered, in particular with
respect to NDR1/2. More specifically, the putative roles
of LATS/NDR as sensors and mediators of internal and
external mechanical forces, upstream of YAP/TAZ, are
exciting avenues to be explored in the future.
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